Skip to main content
Clinical Trials/ACTRN12616000553471
ACTRN12616000553471CompletedPhase 4

Efficacy and safety of dihydroartemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Bosaso, Puntland, Somalia.

Ministry of Health of Puntland0 sites88 target enrollmentStarted: April 29, 2016Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
88

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment
Masking
Open (masking not used)

Eligibility Criteria

Ages
6 Months to 60 Years (—)
Sex
All

Inclusion Criteria

  • 1. age between six months and 60 years with the exception of 12-17 years old female minors and unmarried females 18 years and above;
  • 2. mono-infection with P. falciparum detected by microscopy;
  • 3. parasitaemia of 500–200,000/microliter asexual forms;
  • 4. presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h
  • 5. ability to swallow oral medication;
  • 6. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
  • 7. informed consent from the patient or from a parent or guardian in the case of children aged less than 18 years.
  • 8. informed assent from any minor participant aged from 12 to 18 years; and
  • 9.. consent for pregnancy testing from married female of 18 years and above.

Exclusion Criteria

  • 1. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
  • 2. weight under 5 kg;
  • 3. mixed or mono-infection with another Plasmodium species detected by microscopy;
  • 4. presence of severe malnutrition defined as a child aged 6-60 months has a mid-upper arm circumference below 115 mm)
  • 5. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
  • 6. regular medication, which may interfere with antimalarial pharmacokinetics;
  • 7. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
  • 8. a positive pregnancy test or breastfeeding of married women aged 18 years and above; and
  • 9. unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age and who are sexually active.

Investigators

Sponsor
Ministry of Health of Puntland

Similar Trials

Not yet recruiting
Phase 4
Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in 6 sentinel sites in IndonesiaInfection - Studies of infection and infectious agentsMalaria
ACTRN12614000753651Ministry of Health1,200
Completed
Phase 4
Efficacy and safety of dihydroartemisinin-piperaquine (DP) in Pailin, Preah Vihear and Rattanakiri, and artesunate-mefloquine (ASMQ) in Preah Vihear for uncomplicated P. falciparum malaria and chloroquine (CQ) for P.vivax malaria in the above 3 sites, Cambodia, 2009Infection - Other infectious diseasesMalaria
ACTRN12612000183886Institude Paster du Cambodge420
Not yet recruiting
Phase 4
Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in 2 sentinel sites in IndonesiaInfection - Studies of infection and infectious agentsMalaria
ACTRN12616001533482Ministry of Health of Indonesia352
Completed
Phase 4
Efficacy and safety of Dihydroartemisinin-Piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in District Headquarter Hospital Zhob of Balochistan province and Tehsil HQ Hospital Sadda Kurram Agency FATA, PakistaMalaria
ACTRN12615001248550Directorate of Malaria Control, Ministry of National Health Services Regulations and Coordination, NIH, Islamabad176
Completed
Phase 4
Efficacy and safety of dihydroaretemisinin+piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Jamame (Lower Juba) Janale (Lower Shabelle) and Jowhar (Middle Shabelle) sites, Somalia.Malaria
ACTRN12616001005448Abdullahi Mohamed Hassan264